# A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

> **NCT03316898** · PHASE1 · WITHDRAWN · sponsor: **Allergan**

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** AGN-242071
- **DRUG:** Placebo
- **DRUG:** Donepezil
- **DRUG:** Memantine

## Key facts

- **NCT ID:** NCT03316898
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-30
- **Primary completion:** 2018-11-04
- **Final completion:** 2018-11-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision to stop the study.
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316898, "A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03316898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*